Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 11 | 2024 | 13483 | 1.220 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2024 | 5388 | 0.900 |
Why?
|
Palliative Care | 11 | 2024 | 3639 | 0.790 |
Why?
|
Terminal Care | 4 | 2024 | 1769 | 0.580 |
Why?
|
Euthanasia | 1 | 2017 | 58 | 0.540 |
Why?
|
Suicide, Assisted | 1 | 2017 | 68 | 0.530 |
Why?
|
Melanoma | 2 | 2024 | 5695 | 0.460 |
Why?
|
Qualitative Research | 2 | 2024 | 3138 | 0.450 |
Why?
|
Quality of Life | 8 | 2024 | 13468 | 0.420 |
Why?
|
Caregivers | 2 | 2024 | 2304 | 0.410 |
Why?
|
Hospice Care | 1 | 2018 | 678 | 0.370 |
Why?
|
Neoplasms | 7 | 2024 | 22344 | 0.360 |
Why?
|
Hypoglycemia | 1 | 2018 | 896 | 0.360 |
Why?
|
Nursing Homes | 1 | 2018 | 1084 | 0.350 |
Why?
|
Decision Making | 2 | 2021 | 3955 | 0.250 |
Why?
|
Veterans | 1 | 2018 | 2667 | 0.230 |
Why?
|
Physicians | 2 | 2022 | 4591 | 0.210 |
Why?
|
California | 2 | 2017 | 1435 | 0.200 |
Why?
|
Immunotherapy | 3 | 2021 | 4746 | 0.190 |
Why?
|
Karnofsky Performance Status | 1 | 2020 | 163 | 0.170 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7424 | 0.170 |
Why?
|
Humans | 34 | 2024 | 766117 | 0.150 |
Why?
|
Aged, 80 and over | 7 | 2024 | 59515 | 0.150 |
Why?
|
Interviews as Topic | 1 | 2024 | 2741 | 0.140 |
Why?
|
Legislation, Medical | 1 | 2017 | 99 | 0.140 |
Why?
|
Advance Directives | 1 | 2018 | 249 | 0.130 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 9527 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 8612 | 0.130 |
Why?
|
Death | 1 | 2021 | 686 | 0.130 |
Why?
|
Uncertainty | 1 | 2021 | 763 | 0.130 |
Why?
|
Patient-Centered Care | 2 | 2024 | 1447 | 0.120 |
Why?
|
Aged | 11 | 2024 | 171219 | 0.120 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3928 | 0.120 |
Why?
|
Adult | 9 | 2024 | 223139 | 0.110 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2018 | 12235 | 0.110 |
Why?
|
Pandemics | 3 | 2022 | 8725 | 0.100 |
Why?
|
Emergency Medicine | 1 | 2022 | 1222 | 0.100 |
Why?
|
Retinal Dehydrogenase | 1 | 2012 | 78 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2021 | 1592 | 0.100 |
Why?
|
Focus Groups | 1 | 2018 | 1459 | 0.100 |
Why?
|
Middle Aged | 10 | 2024 | 223083 | 0.090 |
Why?
|
Emergency Service, Hospital | 5 | 2022 | 7871 | 0.090 |
Why?
|
Advance Care Planning | 1 | 2018 | 698 | 0.090 |
Why?
|
Prognosis | 2 | 2022 | 29912 | 0.090 |
Why?
|
Survivors | 1 | 2021 | 2375 | 0.090 |
Why?
|
Medical Oncology | 1 | 2021 | 2339 | 0.080 |
Why?
|
Multigene Family | 1 | 2012 | 1081 | 0.080 |
Why?
|
Physician-Patient Relations | 1 | 2022 | 3270 | 0.080 |
Why?
|
Female | 12 | 2024 | 396233 | 0.070 |
Why?
|
Hip Fractures | 1 | 2016 | 995 | 0.070 |
Why?
|
Communication | 1 | 2022 | 3909 | 0.070 |
Why?
|
Isoenzymes | 1 | 2012 | 1688 | 0.070 |
Why?
|
Male | 10 | 2024 | 363935 | 0.070 |
Why?
|
Survival Analysis | 1 | 2020 | 10087 | 0.070 |
Why?
|
Mice, SCID | 1 | 2012 | 2626 | 0.070 |
Why?
|
Paroxetine | 1 | 2008 | 181 | 0.070 |
Why?
|
Activities of Daily Living | 1 | 2016 | 2419 | 0.070 |
Why?
|
Retrospective Studies | 6 | 2024 | 81565 | 0.070 |
Why?
|
Recovery of Function | 1 | 2016 | 2971 | 0.060 |
Why?
|
Logistic Models | 1 | 2020 | 13273 | 0.060 |
Why?
|
Hot Flashes | 1 | 2008 | 330 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2012 | 21074 | 0.060 |
Why?
|
Inhibin-beta Subunits | 1 | 2004 | 27 | 0.060 |
Why?
|
Follicle Stimulating Hormone, beta Subunit | 1 | 2004 | 58 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2012 | 3604 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5454 | 0.050 |
Why?
|
Depression | 2 | 2022 | 8230 | 0.050 |
Why?
|
Cost of Illness | 2 | 2024 | 1949 | 0.050 |
Why?
|
Chronic Disease | 1 | 2018 | 9354 | 0.050 |
Why?
|
Activins | 1 | 2004 | 210 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3111 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3233 | 0.050 |
Why?
|
Lung | 1 | 2021 | 10063 | 0.050 |
Why?
|
Receptor, erbB-2 | 1 | 2012 | 2593 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26290 | 0.040 |
Why?
|
Incidence | 1 | 2018 | 21513 | 0.040 |
Why?
|
Inpatients | 2 | 2021 | 2566 | 0.040 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2004 | 1142 | 0.040 |
Why?
|
Transcriptional Activation | 1 | 2004 | 1743 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8038 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2022 | 903 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2022 | 65219 | 0.030 |
Why?
|
United States | 2 | 2023 | 72920 | 0.030 |
Why?
|
Forecasting | 1 | 2022 | 2936 | 0.030 |
Why?
|
Mobility Limitation | 1 | 2016 | 409 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3202 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2022 | 2662 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2022 | 2824 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2024 | 11200 | 0.020 |
Why?
|
Walking | 1 | 2016 | 1198 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54812 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2016 | 1422 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8882 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3407 | 0.020 |
Why?
|
Mice | 2 | 2012 | 81839 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5510 | 0.020 |
Why?
|
Disease Progression | 1 | 2022 | 13616 | 0.010 |
Why?
|
Smad2 Protein | 1 | 2004 | 144 | 0.010 |
Why?
|
Smad3 Protein | 1 | 2004 | 165 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2008 | 1588 | 0.010 |
Why?
|
Smad4 Protein | 1 | 2004 | 194 | 0.010 |
Why?
|
Response Elements | 1 | 2004 | 307 | 0.010 |
Why?
|
Animals | 2 | 2012 | 168800 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10579 | 0.010 |
Why?
|
Dementia | 1 | 2016 | 2741 | 0.010 |
Why?
|
Estrogen Replacement Therapy | 1 | 2008 | 1206 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10811 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2016 | 14747 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18386 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41684 | 0.010 |
Why?
|
MAP Kinase Signaling System | 1 | 2004 | 1490 | 0.010 |
Why?
|
Binding Sites | 1 | 2004 | 6001 | 0.010 |
Why?
|
Trans-Activators | 1 | 2004 | 2849 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2008 | 12426 | 0.010 |
Why?
|
Base Sequence | 1 | 2004 | 12405 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2004 | 5784 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2004 | 17597 | 0.010 |
Why?
|
Cell Line | 1 | 2004 | 15546 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2004 | 5791 | 0.010 |
Why?
|
Rats | 1 | 2004 | 23717 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 9601 | 0.000 |
Why?
|
Mutation | 1 | 2004 | 30209 | 0.000 |
Why?
|
Concepts
(122)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(60)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_